Browsing by Author "Rosanoff, Andrea"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    The Circulating Concentration and 24-h Urine Excretion of Magnesium Dose- and Time-Dependently Respond to Oral Magnesium Supplementation in a Meta-Analysis of Randomized Controlled Trials
    (Oxford, 2016-03) Zhang, Xi; Del Gobbo, Liana C.; Hruby, Adela; Rosanoff, Andrea; He, Ka; Dai, Qi; Costello, Rebecca B.; Zhang, Wen; Song, Yiqing; Epidemiology, School of Public Health
    Background: Accurate determination of Mg status is important for improving nutritional assessment and clinical risk stratification. Objective: We aimed to quantify the overall responsiveness of Mg biomarkers to oral Mg supplementation among adults without severe diseases and their dose- and time responses using available data from randomized controlled trials (RCTs). Methods: We identified 48 Mg supplementation trials (n = 2131) through searches of MEDLINE and the Cochrane Library up to November 2014. Random-effects meta-analysis was used to estimate weighted mean differences of biomarker concentrations between intervention and placebo groups. Restricted cubic splines were used to determine the dose- and time responses of Mg biomarkers to supplementation. Results: Among the 35 biomarkers assessed, serum, plasma, and urine Mg were most commonly measured. Elemental Mg supplementation doses ranged from 197 to 994 mg/d. Trials ranged from 3 wk to 5 y (median: 12 wk). Mg supplementation significantly elevated circulating Mg by 0.04 mmol/L (95% CI: 0.02, 0.06) and 24-h urine Mg excretion by 1.52 mmol/24 h (95% CI: 1.20, 1.83) as compared to placebo. Circulating Mg concentrations and 24-h urine Mg excretion responded to Mg supplementation in a dose- and time-dependent manner, gradually reaching a steady state at doses of 300 mg/d and 400 mg/d, or after ~20 wk and 40 wk, respectively (all P-nonlinearity ≤ 0.001). The higher the circulating Mg concentration at baseline, the lower the responsiveness of circulating Mg to supplementation, and the higher the urinary excretion (all P-linearity < 0.05). In addition, RBC Mg, fecal Mg, and urine calcium were significantly more elevated by Mg supplementation than by placebo (all P-values < 0.05), but there is insufficient evidence to determine their responses to increasing Mg doses. Conclusions: This meta-analysis of RCTs demonstrated significant dose- and time responses of circulating Mg concentration and 24-h urine Mg excretion to oral Mg supplementation.
  • Thumbnail Image
    Item
    Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials
    (Elsevier, 2016-08) Zhang, Xi; Li, Yufeng; Del Gobbo, Liana C.; Rosanoff, Andrea; Wang, Jiawei; Zhang, Wen; Song, Yiqing; Department of Epidemiology, Richard M. Fairbanks School of Public Health
    The antihypertensive effect of magnesium (Mg) supplementation remains controversial. We aimed to quantify the effect of oral Mg supplementation on blood pressure (BP) by synthesizing available evidence from randomized, double-blind, placebo-controlled trials. We searched trials of Mg supplementation on normotensive and hypertensive adults published up to February 1, 2016 from MEDLINE and EMBASE databases; 34 trials involving 2028 participants were eligible for this meta-analysis. Weighted mean differences of changes in BP and serum Mg were calculated by random-effects meta-analysis. Mg supplementation at a median dose of 368 mg/d for a median duration of 3 months significantly reduced systolic BP by 2.00 mm Hg (95% confidence interval, 0.43–3.58) and diastolic BP by 1.78 mm Hg (95% confidence interval, 0.73–2.82); these reductions were accompanied by 0.05 mmol/L (95% confidence interval, 0.03, 0.07) elevation of serum Mg compared with placebo. Using a restricted cubic spline curve, we found that Mg supplementation with a dose of 300 mg/d or duration of 1 month is sufficient to elevate serum Mg and reduce BP; and serum Mg was negatively associated with diastolic BP but not systolic BP (all P<0.05). In the stratified analyses, a greater reduction in BP tended to be found in trials with high quality or low dropout rate (all P values for interaction <0.05). However, residual heterogeneity may still exist after considering these possible factors. Our findings indicate a causal effect of Mg supplementation on lowering BPs in adults. Further well-designed trials are warranted to validate the BP-lowering efficacy of optimal Mg treatment.
  • Thumbnail Image
    Item
    Magnesium intake was inversely associated with hostility among American young adults
    (Elsevier, 2021) Lyu, Chen; Tsinovoi, Cari L.; Xun, Pengcheng; Song, Yiqing; Pu, Yongjia; Rosanoff, Andrea; Iribarren, Carlos; Schreiner, Pamela J.; Shikany, James M.; Jacobs, David R.; Kahe, Ka; Epidemiology, Richard M. Fairbanks School of Public Health
    Hostility is a complex personality trait associated with many cardiovascular risk factor phenotypes. Although magnesium intake has been related to mood and cardio-metabolic disease, its relation with hostility remains unclear. We hypothesize that high total magnesium intake is associated with lower levels of hostility because of its putative antidepressant mechanisms. To test the hypothesis, we prospectively analyzed data in 4,716 young adults aged 18-30 years at baseline (1985-1986) from four U.S. cities over five years of follow-up using data from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Magnesium intake was estimated from a dietary history questionnaire plus supplements at baseline. Levels of hostility were assessed using the Cook-Medley scale at baseline and year 5 (1990-1991). Generalized estimating equations were applied to estimate the association of magnesium intake with hostility as repeated measures at the two time-points (baseline and year 5). General linear model was used to determine the association between magnesium intake and change in hostility over 5 years. After adjustment for socio-demographic and major lifestyle factors, a significant inverse association was observed between magnesium intake and hostility level over 5 years of follow-up. Beta coefficients (95% CI) across higher quintiles of magnesium intake were 0 (reference), -1.28 (-1.92, -0.65), -1.45 (-2.09, -0.81), -1.41 (-2.08, -0.75) and -2.16 (-2.85, -1.47), respectively (Plinear-trend<.01). The inverse association was independent of socio-demographic and major lifestyle factors, supplement use, and depression status at year 5. This prospective study provides evidence that in young adults, high magnesium intake was inversely associated with hostility level independent of socio-demographic and major lifestyle factors.
  • Thumbnail Image
    Item
    Recommendation on an updated standardization of serum magnesium reference ranges
    (Springer, 2022-06-10) Rosanoff, Andrea; Wes, Christina; Elin, Ronald J.; Micke, Oliver; Baniasadi, Shadi; Barbagallo, Mario; Campbell, Emily; Cheng, Fu-Chou; Costello, Rebecca B.; Gamboa-Gomez, Claudia; Guerrero-Romero, Fernando; Gletsu-Miller, Nana; von Ehrlich, Bodo; Iotti, Stefano; Kahe, Ka; Kim, Dae Jung; Kisters, Klaus; Kolisek, Martin; Kraus, Anton; Maier, Jeanette A.; Maj-Zurawska, Magdalena; Merolle, Lucia; Nechifor, Mihai; Pourdowlat, Guitti; Shechter, Michael; Song, Yiqing; Teoh, Yee Ping; Touyz, Rhian M.; Wallace, Taylor C.; Yokota, Kuninobu; Wolf, Federica; the MaGNet Global Magnesium Project (MaGNet); Epidemiology, Richard M. Fairbanks School of Public Health
    Purpose Serum magnesium is the most frequently used laboratory test for evaluating clinical magnesium status. Hypomagnesemia (low magnesium status), which is associated with many chronic diseases, is diagnosed using the serum magnesium reference range. Currently, no international consensus for a magnesemia normal range exists. Two independent groups designated 0.85 mmol/L (2.07 mg/dL; 1.7 mEq/L) as the low cut-off point defining hypomagnesemia. MaGNet discussions revealed differences in serum magnesium reference ranges used by members’ hospitals and laboratories, presenting an urgent need for standardization. Methods We gathered and compared serum magnesium reference range values from our institutions, hospitals, and colleagues worldwide. Results Serum magnesium levels designating “hypomagnesemia” differ widely. Of 43 collected values, only 2 met 0.85 mmol/L as the low cut-off point to define hypomagnesemia. The remainder had lower cut-off values, which may underestimate hypomagnesemia diagnosis in hospital, clinical, and research assessments. Current serum magnesium reference ranges stem from “normal” populations, which unknowingly include persons with chronic latent magnesium deficit (CLMD). Serum magnesium levels of patients with CLMD fall within widely used “normal” ranges, but their magnesium status is too low for long-term health. The lower serum magnesium reference (0.85 mmol/L) proposed specifically prevents the inclusion of patients with CLMD. Conclusions Widely varying serum magnesium reference ranges render our use of this important medical tool imprecise, minimizing impacts of low magnesium status or hypomagnesemia as a marker of disease risk. To appropriately diagnose, increase awareness of, and manage magnesium status, it is critical to standardize lower reference values for serum magnesium at 0.85 mmol/L (2.07 mg/dL; 1.7 mEq/L).
  • Thumbnail Image
    Item
    The magnesium global network (MaGNet) to promote research on magnesium in diseases focusing on covid-19
    (JLE, 2021) Wolf, Federica I.; Maier, Jeanette A.; Rosanoff, Andrea; Barbagallo, Mario; Baniasadi, Shadi; Castiglioni, Sara; Cheng, Fu-Chou; Colaneri Day, Sherrie; Costello, Rebecca B.; Dominguez, Ligia J.; Elin, Ronald J.; Gamboa-Gomez, Claudia; Guerrero-Romero, Fernando; Kahe, Ka; Kisters, Klaus; Kolisek, Martin; Kraus, Anton; Iotti, Stefano; Mazur, Andre; Mercado-Atri, Moises; Merolle, Lucia; Micke, Oliver; Gletsu-Miller, Nana; Nielsen, Forrest; O-Uchi, Jin; Piazza, Ornella; Plesset, Michael; Pourdowlat, Guitti; Rios, Francisco J.; Rodriguez-Moran, Martha; Scarpati, Giuliana; Shechter, Michael; Song, Yiqing; Spence, Lisa A.; Touyz, Rhian M.; Trapani, Valentina; Veronese, Nicola; von Ehrlich, Bodo; Vormann, Juergen; Wallace, Taylor C.; CMER Center for Magnesium Education, Research; Gesellschaft für Magnesium-Forschung e.V. Germany; SDRM Society (International Society for the Development of Research on Magnesium); Epidemiology, School of Public Health